Introduction
Biologic therapies have revolutionized inflammatory bowel disease (IBD) management, dramatically improving disease control[1]. However, their impact on overall mortality patterns remains incompletely characterized[2]. This study analyzed the evolution of mortality causes in IBD patients across distinct therapeutic eras. We hypothesized a "Biologic Era Paradox"a shift from IBD-specific mortality toward systemic causes, particularly cardiovascular disease (CVD) driven by chronic inflammation, infections from immunosuppression, and malignancies in an aging cohort[3].
Aims & Methods
We analyzed CDC WONDER Multiple Cause of Death records (1990-2024), identifying deaths where IBD was a contributing cause. We stratified the study into three eras: Pre-Biologic (1990-1998), Early Biologic (1999-2010), and Widespread Biologic (2011-2025). Contributing causes were categorized via ICD-10 codes into CVD, neoplasms, infections, and digestive/IBD-specific causes. We calculated CDC age-standardized and population-adjusted mortality rates, analyzing 33,639 IBD-related deaths.
Results
The introduction of biologics in 1999 correlated with a dramatic 69% reduction in absolute IBD-related deaths, declining from approximately 1,870 in 1998 to 580 in 1999, alongside a drop in population-adjusted mortality rates from 0.8-1.0 per 100,000 in the Pre-Biologic Era to 0.6-0.7 per 100,000 during the Biologic eras. However, this overall reduction was accompanied by a fundamental shift in mortality patterns. While digestive/IBD-specific causes accounted for 100% of recorded deaths (14,828) in the Pre-Biologic Era, cardiovascular disease (CVD) emerged post-biologics as the dominant contributing cause, accounting for 56.2% (1999-2010), 58.4% (2011-2020), and 54.7% (2021-2025) of deaths. Concurrently, infection-related deaths remained consistently substantial across the three biologic cohorts (35.6%, 33.1%, and 33.8%), suggesting a balanced risk-benefit profile for current immunosuppressive strategies, whereas neoplasm-related deaths demonstrated a concerning 49% relative increase, rising from 4.5% in the Early Biologic Era to 6.7% in 2021-2025. Finally, sex-stratified analysis confirmed these trends across demographics, with CVD predominating as the leading contributing cause of death in both males and females during the biologic eras.
Conclusion
This 35-year analysis demonstrates that while biologic therapies achieved a ~70% reduction in overall IBD mortality, a paradigm shift occurred in causes of death. The emergence of CVD as the leading contributor represents a "Silver Tsunami," as patients now survive to face age-related systemic diseases compounded by chronic inflammation. Stable infection-related mortality suggests immunosuppression achieves a reasonable balance, but the relative increase in malignancies warrants enhanced surveillance. These findings mandate a shift toward holistic IBD care, integrating aggressive cardiovascular risk management, infection prevention, and cancer screening for an aging, immunosuppressed population.
References
1) Appiah, J. K., Hayat, U., Garg, N., Asante, R., Donneyong, E., Haider, M. U., Patel, P., Khan, Z., & Siddiqui, A. A. (2025). Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review. Journal of clinical medicine, 14(17), 6119. https://doi.org/10.3390/jcm14176119
2)Selinger, C. P., Rosiou, K., & Lenti, M. V. (2024). Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?. BMJ open gastroenterology, 11(1), e001225. https://doi.org/10.1136/bmjgast-2023-001225
3) Follin-Arbelet, B., Cvancarova Småstuen, M., Hovde, Ø., Jelsness-Jørgensen, L. P., & Moum, B. (2023). Mortality in Patients with Inflammatory Bowel Disease: Results from 30 Years of Follow-up in a Norwegian Inception Cohort (the IBSEN study). Journal of Crohn's & colitis, 17(4), 497–503. https://doi.org/10.1093/ecco-jcc/jjac156
